Liposomal Clodronate as a Therapy for Autoimmune Hemolytic Anemia
Tech ID: 02-07
NOTE: THIS TECHNOLOGY IS EXPERIMENTAL AND THEREFORE IT IS NOT AVAILABLE TO HUMANS. IT HAS ONLY BEEN TESTED IN MICE
Summary - This invention is using liposomal clodronate as a therapy for autoimmune hemolytic anemia.
Potential Applications
- Therapy for autoimmune hemolytic anemia
- The therapy is applicable to both humans and companion animals
Advantages of Invention
- The method is less invasive than surgery (splenectomy)
- Decrease use of steroids
- Decrease side effects
State of Development
- The efficacy of this therapy has been demonstrated by some strong in vivo data obtained in mice.
- Using a mouse model in which animals were given anti red blood cell antibodies, treatment with liposomal clodronate substantially decreased red blood cell destruction.
- In addition, this effect was detected within hours and lasted at least a week.
Further R&D Required - Additional in vivo studies with other animal models.
Licensing Potential - Available for licensing.
Patent Status - U.S. Patent # 7,090,865
Inventors - Mike Jordan, MD, Philippa Marrack, PhD, and John Kappler, PhD
Publications
Jordan et al. (2003) Blood: 101(2): 594-601
Mathes et al. (2006) Exp Hemat; 34:1393-1402
For Further Information, Contact:
Emmanuel Hilaire, PhD
Licensing Associate
Intellectual Property and Technology Commercialization Program
National Jewish Health
1400 Jackson Street, Room M206b
Denver, CO 80206
Voice: (303) 398-1262
Fax: (303) 270-2352
HilaireE@njc.org
